UroGen Pharma Ltd. Other-than-temporary Impairment Loss, Debt Securities, Portion Recognized in Earnings
UroGen Pharma Ltd. (URGN) reported Other-than-temporary Impairment Loss, Debt Securities, Portion Recognized in Earnings of $0 for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings · last filed 2021-08-04
- UroGen Pharma Ltd. other-than-temporary impairment loss, debt securities, portion recognized in earnings for the quarter ending 2021-06-30 was $0.00.
- UroGen Pharma Ltd. other-than-temporary impairment loss, debt securities, portion recognized in earnings for the quarter ending 2021-03-31 was $0.00.
- UroGen Pharma Ltd. other-than-temporary impairment loss, debt securities, portion recognized in earnings for the quarter ending 2020-12-31 was $0.00.
- UroGen Pharma Ltd. other-than-temporary impairment loss, debt securities, portion recognized in earnings for the quarter ending 2020-09-30 was $0.00.
- UroGen Pharma Ltd. other-than-temporary impairment loss, debt securities, portion recognized in earnings for fiscal 2020 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Portion Recognized in Earnings 3 month | Other-than-temporary Impairment Loss, Debt Securities, Portion Recognized in Earnings 6 month | Other-than-temporary Impairment Loss, Debt Securities, Portion Recognized in Earnings 9 month | Other-than-temporary Impairment Loss, Debt Securities, Portion Recognized in Earnings 12 month |
|---|---|---|---|---|
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | $0.00 derived: sum of 3 quarters · filed 2021-08-04 | $0.00 derived: sum of 4 quarters · filed 2021-08-04 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 | $0.00 derived: sum of 2 quarters · filed 2021-05-13 | $0.00 derived: sum of 3 quarters · filed 2021-05-13 | $0.00 derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $0.00 derived: sum of 2 quarters · filed 2021-03-18 | $0.00 derived: sum of 3 quarters · filed 2021-03-18 | $0.00 10-K · filed 2021-03-18 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | ||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |